CARA THERAPEUTICS INC's ticker is CARA and the CUSIP is 140755109. A total of 157 filers reported holding CARA THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 0.47 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $226,570 | -72.0% | 134,863 | -52.8% | 0.00% | – |
| Q2 2023 | $808,958 | -45.7% | 285,851 | -5.9% | 0.00% | – |
| Q1 2023 | $1,490,799 | -53.0% | 303,625 | +2.7% | 0.00% | -100.0% |
| Q4 2022 | $3,173,993 | +27.6% | 295,530 | +11.2% | 0.00% | 0.0% |
| Q3 2022 | $2,487,000 | +87.6% | 265,743 | +82.8% | 0.00% | – |
| Q2 2022 | $1,326,000 | -14.7% | 145,336 | +13.6% | 0.00% | – |
| Q1 2022 | $1,555,000 | +1.3% | 127,947 | +1.5% | 0.00% | – |
| Q4 2021 | $1,535,000 | -67.6% | 126,047 | -58.9% | 0.00% | -100.0% |
| Q3 2021 | $4,743,000 | -12.4% | 307,008 | -19.1% | 0.00% | 0.0% |
| Q2 2021 | $5,413,000 | -43.7% | 379,326 | -14.4% | 0.00% | -50.0% |
| Q1 2021 | $9,617,000 | +5.8% | 442,989 | -26.3% | 0.00% | 0.0% |
| Q4 2020 | $9,093,000 | +16.1% | 600,947 | -2.4% | 0.00% | 0.0% |
| Q3 2020 | $7,833,000 | +41.7% | 615,559 | +90.5% | 0.00% | 0.0% |
| Q2 2020 | $5,526,000 | +97.1% | 323,159 | +52.3% | 0.00% | +100.0% |
| Q1 2020 | $2,804,000 | -31.1% | 212,224 | -15.9% | 0.00% | 0.0% |
| Q4 2019 | $4,068,000 | -26.0% | 252,485 | -16.0% | 0.00% | -50.0% |
| Q3 2019 | $5,495,000 | +185.5% | 300,638 | +235.7% | 0.00% | +100.0% |
| Q2 2019 | $1,925,000 | +71.4% | 89,544 | +56.4% | 0.00% | – |
| Q1 2019 | $1,123,000 | -8.9% | 57,237 | -39.7% | 0.00% | – |
| Q4 2018 | $1,233,000 | -67.7% | 94,849 | -40.6% | 0.00% | -100.0% |
| Q3 2018 | $3,822,000 | -5.8% | 159,558 | -24.7% | 0.00% | 0.0% |
| Q2 2018 | $4,058,000 | +990.9% | 211,893 | +603.9% | 0.00% | – |
| Q1 2018 | $372,000 | -61.4% | 30,102 | -61.8% | 0.00% | – |
| Q4 2017 | $964,000 | -9.2% | 78,811 | +1.6% | 0.00% | – |
| Q3 2017 | $1,062,000 | -68.2% | 77,536 | -64.2% | 0.00% | – |
| Q2 2017 | $3,337,000 | +1444.9% | 216,804 | +1742.0% | 0.00% | – |
| Q1 2017 | $216,000 | -23.4% | 11,770 | -61.2% | 0.00% | – |
| Q4 2016 | $282,000 | +22.1% | 30,333 | +9.6% | 0.00% | – |
| Q3 2016 | $231,000 | +71.1% | 27,688 | -1.7% | 0.00% | – |
| Q2 2016 | $135,000 | +70.9% | 28,157 | +122.5% | 0.00% | – |
| Q1 2016 | $79,000 | – | 12,657 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC | 2,204,449 | $10,824 | 1.35% |
| KINGDON CAPITAL MANAGEMENT, L.L.C. | 1,233,000 | $6,054,030 | 1.14% |
| Chescapmanager LLC | 1,160,392 | $5,698 | 0.90% |
| DISCIPLINED GROWTH INVESTORS INC /MN | 1,732,375 | $8,505,961 | 0.22% |
| XTX Topco Ltd | 107,610 | $528,365 | 0.11% |
| IQ EQ FUND MANAGEMENT (IRELAND) Ltd | 84,530 | $415,042 | 0.08% |
| PINNACLE ASSOCIATES LTD | 679,413 | $3,335,918 | 0.07% |
| PDT Partners, LLC | 102,010 | $500,869 | 0.07% |
| FARALLON CAPITAL MANAGEMENT LLC | 1,995,370 | $9,797,267 | 0.05% |
| AXQ CAPITAL, LP | 27,760 | $136,302 | 0.05% |